Global Antidiabetics Market
Global Antidiabetics Market Report 2024 - A $313.9 Billion Market by 2034, with CAGR of 10.9% During 2024-2034
March 18, 2024 05:10 ET | Research and Markets
Dublin, March 18, 2024 (GLOBE NEWSWIRE) -- The "Global Antidiabetics Market by Product Type, by Application, by Distribution channel, and By Region" report has been added to ...
Global Diabetes Care Drugs Market
Global Diabetes Care Drugs Market to Reach $103 Billion by 2027: Asia-Pacific is Poised to Show a Considerable Growth Rate
March 06, 2023 09:48 ET | Research and Markets
Dublin, March 06, 2023 (GLOBE NEWSWIRE) -- The "Global Diabetes Care Drugs Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's offering.The global diabetes care...
COVID OUT clinical t
COVID OUT clinical trial suggests metformin effective at reducing odds of serious outcomes for COVID-19 patients seeking early treatment
August 18, 2022 09:00 ET | University of Minnesota Medical School
MINNEAPOLIS/ST. PAUL, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Published in the New England Journal of Medicine, researchers — led by the University of Minnesota Medical School and School of Public Health...
22157.jpg
Investigation Report on China's Metformin Market 2021-2025
December 31, 2021 05:33 ET | Research and Markets
Dublin, Dec. 31, 2021 (GLOBE NEWSWIRE) -- The "Investigation Report on China's Metformin Market 2021-2025" report has been added to ResearchAndMarkets.com's offering. The analyst expects that with...
Logo.jpg
[UPDATED] CURATIVE BIOTECHNOLOGY ANNOUNCES OCULAR TOLERANCE EVALUATION OF METFORMIN EYE DROP FORMULATIONS FOR TREATMENT OF MACULAR DEGENERATION
November 24, 2021 15:05 ET | Curative Biotechnology, Inc. 
Company’s First In-license Pipeline Product to Enter Pre-clinical Studies Boca Raton, FL, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBT) (“Curative Biotech” or the...
Logo.jpg
CURATIVE BIOTECHNOLOGY ANNOUNCES OCULAR TOLERANCE EVALUATION OF METFORMIN EYE DROP FORMULATIONS FOR TREATMENT OF MACULAR DEGENERATION
November 24, 2021 10:00 ET | Curative Biotechnology, Inc. 
Company’s First In-license Pipeline Product to Enter Pre-clinical Studies Boca Raton, FL, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBT) (“Curative Biotech” or the...
22157.jpg
Global Antidiabetic Drug Markets Report 2021: A-Glucosidase Inhibitors, Biguanides, DPP-IV Inhibitors, Meglitinides, Sulfonylureas, Thiazolidinediones - Forecast to 2026
August 25, 2021 09:23 ET | Research and Markets
Dublin, Aug. 25, 2021 (GLOBE NEWSWIRE) -- The "Global Antidiabetic Drug Market (2021-2026) by Drug Type, Diabetic Type, Patient, Geography, Competitive Analysis and the Impact of Covid-19 with...
University of Minnesota Medical School launches clinical trial studying metformin treatment for COVID-19
March 15, 2021 09:54 ET | University of Minnesota Medical School
Minneapolis / St. Paul, March 15, 2021 (GLOBE NEWSWIRE) -- A new multi-site clinical trial led by the University of Minnesota Medical School is studying the effectiveness of metformin, a generic...
Type 2 Diabetes Trial Results Presented by Study Investigators at American Diabetes Association Annual Meeting
June 18, 2014 23:19 ET | Mesoblast
NEW YORK and MELBOURNE, Australia, June 18, 2014 (GLOBE NEWSWIRE) -- Results from the Phase 2 trial of Mesoblast's proprietary adult stem cells in type 2 diabetes patients have been presented by Jay...